DK2208784T3 - Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof - Google Patents

Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof

Info

Publication number: DK2208784T3
Authority: DK; Denmark
Prior art keywords: antibody; glypican; cell proliferation; proliferation inhibitors; containing anti
Prior art date: 2001-06-22

Application number

DK10003378.6T

Other languages

English (en)

Inventor

Hiroyuki Aburatani

Tetsuo Nakamura

Masayuki Tsuchiya

Original Assignee

Chugai Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-22

Filing date

2002-06-21

Publication date

2013-03-18

2002-06-21 Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd

2013-03-18 Application granted granted Critical

2013-03-18 Publication of DK2208784T3 publication Critical patent/DK2208784T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Mycology (AREA)
Hematology (AREA)
Oncology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

DK10003378.6T 2001-06-22 2002-06-21 Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof DK2208784T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2001189443		2001-06-22
EP07002896A EP1780273B1 (en)	2001-06-22	2002-06-21	Cell proliferation inhibitors containing anti-glypican 3 antibody

Publications (1)

Publication Number	Publication Date
DK2208784T3 true DK2208784T3 (da)	2013-03-18

Family

ID=19028362

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK10003378.6T DK2208784T3 (da)	2001-06-22	2002-06-21	Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof
DK02741243T DK1411118T3 (da)	2001-06-22	2002-06-21	Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK02741243T DK1411118T3 (da)	2001-06-22	2002-06-21	Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof

Country Status (15)

Country	Link
US (3)	US20040236080A1 (da)
EP (3)	EP2208784B1 (da)
JP (7)	JP4281869B2 (da)
KR (3)	KR100877176B1 (da)
CN (2)	CN101240022B (da)
AT (2)	ATE407204T1 (da)
AU (2)	AU2002315857B2 (da)
CA (1)	CA2451493C (da)
CY (1)	CY1113854T1 (da)
DE (2)	DE60228721D1 (da)
DK (2)	DK2208784T3 (da)
ES (3)	ES2312586T3 (da)
HK (2)	HK1079547A1 (da)
PT (2)	PT1411118E (da)
WO (1)	WO2003000883A1 (da)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7361336B1 (en) *	1997-09-18	2008-04-22	Ivan Bergstein	Methods of cancer therapy targeted against a cancer stem line
DE60228721D1 (en) *	2001-06-22	2008-10-16	Chugai Pharmaceutical Co Ltd	Zellproliferationsinhibitoren mit anti-glypican-3-antikörper
WO2004022597A1 (ja) *	2002-09-04	2004-03-18	Chugai Seiyaku Kabushiki Kaisha	Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
BRPI0311233B8 (pt)	2002-05-23	2021-07-27	Sunnybrook And Womens College Health Sciences Centre	métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra
EP1671645A4 (en) *	2003-09-04	2007-07-25	Chugai Pharmaceutical Co Ltd	REMEDIES AND MEDIUM FOR DETECTING GALLENGIFT CANCER
NZ579543A (en)	2004-07-09	2011-07-29	Chugai Pharmaceutical Co Ltd	Anti-glypican 3 antibody
JP4733042B2 (ja)	2004-08-24	2011-07-27	中外製薬株式会社	抗グリピカン３抗体を用いたアジュバント療法
WO2006046751A1 (ja) *	2004-10-26	2006-05-04	Chugai Seiyaku Kabushiki Kaisha	糖鎖改変抗グリピカン３抗体
JP5620626B2 (ja)	2005-03-31	2014-11-05	中外製薬株式会社	会合制御によるポリペプチド製造方法
EP1901573A1 (en)	2005-08-03	2008-03-19	Matsushita Electric Industrial Co., Ltd.	Base station apparatus, communication terminal apparatus, and multicarrier communication method
US20070087005A1 (en)	2005-10-14	2007-04-19	Lazar Gregory A	Anti-glypican-3 antibody
US7723043B2 (en)	2006-01-04	2010-05-25	Picobella, Lp	Methods for screening for prostate cancer
EP3345616A1 (en)	2006-03-31	2018-07-11	Chugai Seiyaku Kabushiki Kaisha	Antibody modification method for purifying bispecific antibody
EP3056568B1 (en)	2006-03-31	2021-09-15	Chugai Seiyaku Kabushiki Kaisha	Methods for controlling blood pharmacokinetics of antibodies
ME02345B (me)	2007-07-17	2016-08-31	Squibb & Sons Llc	MONOKLONSKA ANTlTELA PROTIV GLIPIKANA-3
US9096651B2 (en)	2007-09-26	2015-08-04	Chugai Seiyaku Kabushiki Kaisha	Method of modifying isoelectric point of antibody via amino acid substitution in CDR
DK3059246T3 (da)	2007-09-26	2018-10-01	Chugai Pharmaceutical Co Ltd	Modificeret konstant region i et antistof
RU2445366C2 (ru)	2007-09-28	2012-03-20	Чугаи Сейяку Кабусики Кайся	Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме
BRPI0821110B8 (pt) *	2007-12-05	2021-05-25	Chugai Pharmaceutical Co Ltd	anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
CL2009000647A1 (es) *	2008-04-04	2010-06-04	Chugai Pharmaceutical Co Ltd	Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
HRP20240722T1 (hr)	2008-04-11	2024-08-30	Chugai Seiyaku Kabushiki Kaisha	Molekula koja se veže na antigene, koja se može ponavljano vezati na dvje ili više molekula antigena
TWI440469B (zh)	2008-09-26	2014-06-11	Chugai Pharmaceutical Co Ltd	Improved antibody molecules
US20120071634A1 (en)	2009-03-19	2012-03-22	Chugai Seiyaku Kabushiki Kaisha	Antibody Constant Region Variant
EP2409991B1 (en)	2009-03-19	2017-05-03	Chugai Seiyaku Kabushiki Kaisha	Antibody constant region variant
JP5837821B2 (ja)	2009-09-24	2015-12-24	中外製薬株式会社	抗体定常領域改変体
US10435458B2 (en)	2010-03-04	2019-10-08	Chugai Seiyaku Kabushiki Kaisha	Antibody constant region variants with reduced Fcgammar binding
TWI452135B (zh)	2010-11-17	2014-09-11	中外製藥股份有限公司	A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
RU2658504C9 (ru)	2010-11-30	2018-08-21	Чугаи Сейяку Кабусики Кайся	Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
KR20240025059A (ko)	2010-11-30	2024-02-26	추가이 세이야쿠 가부시키가이샤	세포상해 유도 치료제
US20120190049A1 (en) *	2010-12-10	2012-07-26	University Of Washington Through Its Center For Commercialization	Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles
SG192945A1 (en)	2011-02-25	2013-09-30	Chugai Pharmaceutical Co Ltd	Fcgriib-specific fc antibody
AU2012233313C1 (en)	2011-03-30	2017-08-03	Chugai Seiyaku Kabushiki Kaisha	Method for altering plasma retention and immunogenicity of antigen-binding molecule
EP3939996A1 (en)	2011-09-30	2022-01-19	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817745A (zh)	2011-09-30	2018-05-16	日商中外製藥股份有限公司	具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US20140335089A1 (en)	2011-09-30	2014-11-13	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule for promoting elimination of antigens
JP6352634B2 (ja)	2011-09-30	2018-07-04	中外製薬株式会社	標的抗原に対する免疫応答を誘導する抗原結合分子
EP3617313A1 (en)	2011-10-05	2020-03-04	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain
EP2818183B1 (en)	2012-02-24	2020-04-01	Chugai Seiyaku Kabushiki Kaisha	ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA Fc RIIB
CN104487457B (zh)	2012-05-30	2018-01-26	中外制药株式会社	靶组织特异性抗原结合分子
US9409994B2 (en)	2012-06-01	2016-08-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	High-affinity monoclonal antibodies to glypican-3 and use thereof
TWI693073B (zh)	2012-12-21	2020-05-11	日商中外製藥股份有限公司	對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
EP3557260B1 (en)	2012-12-21	2022-05-18	Chugai Seiyaku Kabushiki Kaisha	Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
SG11201602261VA (en)	2013-09-27	2016-04-28	Chugai Pharmaceutical Co Ltd	Method for producing polypeptide heteromultimer
US10961530B2 (en)	2013-12-04	2021-03-30	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
AR100353A1 (es)	2014-05-08	2016-09-28	Chugai Pharmaceutical Co Ltd	Droga de direccionamiento a glipicano 3 (gpc3) que se administra a un paciente que responde a la terapia con drogas de direccionamiento a gpc3
US9926377B2 (en) *	2014-05-22	2018-03-27	Genentech, Inc.	Anti-GPC3 antibodies and immunoconjugates
MA40764A (fr)	2014-09-26	2017-08-01	Chugai Pharmaceutical Co Ltd	Agent thérapeutique induisant une cytotoxicité
CN104829704B (zh) *	2014-12-15	2016-08-17	河北省科学院生物研究所	一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株
PE20171111A1 (es)	2014-12-19	2017-08-07	Chugai Pharmaceutical Co Ltd	Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso
EA201791366A1 (ru)	2014-12-19	2018-02-28	Чугаи Сейяку Кабусики Кайся	Антитела к c5 и способы их применения
WO2016112423A1 (en) *	2015-01-16	2016-07-21	Minomic International Ltd.	Glypican epitopes and uses thereof
JP2018510842A (ja)	2015-02-05	2018-04-19	中外製薬株式会社	イオン濃度依存的抗原結合ドメインを含む抗体、Ｆｃ領域改変体、ＩＬ−８に結合する抗体、およびその使用
TWI759261B (zh)	2015-02-27	2022-04-01	日商中外製藥股份有限公司	Ｉｌ－６受體抗體用於製備醫藥組成物的用途
WO2016159213A1 (ja)	2015-04-01	2016-10-06	中外製薬株式会社	ポリペプチド異種多量体の製造方法
US11376326B2 (en)	2015-07-01	2022-07-05	Chugai Seiyaku Kabushiki Kaisha	GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
SG11201800989RA (en) *	2015-08-03	2018-03-28	Carsgen Therapeutics Ltd	Antibody against glypican-3 and application thereof
KR101796688B1 (ko)	2015-10-29	2017-12-01	재단법인 목암생명과학연구소	신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
HUE067793T2 (hu)	2015-11-09	2024-11-28	Childrens Hospital Philadelphia	Glipikán 2 mint rákmarker és terápiás célpont
EP3394098A4 (en)	2015-12-25	2019-11-13	Chugai Seiyaku Kabushiki Kaisha	ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
SG11201803989WA (en)	2015-12-28	2018-06-28	Chugai Pharmaceutical Co Ltd	Method for promoting efficiency of purification of fc region-containing polypeptide
SG11201807936VA (en)	2016-03-14	2018-10-30	Chugai Pharmaceutical Co Ltd	Cell injury inducing therapeutic drug for use in cancer therapy
EP4112641A1 (en) *	2016-03-15	2023-01-04	Chugai Seiyaku Kabushiki Kaisha	Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
CN109689099B (zh)	2016-08-05	2023-02-28	中外制药株式会社	用于预防或治疗il-8相关疾病的组合物
JP7125347B2 (ja)	2016-08-22	2022-08-24	中外製薬株式会社	ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
TWI776827B (zh)	2016-11-28	2022-09-11	日商中外製藥股份有限公司	能夠調節配體結合活性的配體結合分子
JP7185884B2 (ja)	2017-05-02	2022-12-08	国立研究開発法人国立精神・神経医療研究センター	Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
EP3684413A1 (en)	2017-09-20	2020-07-29	Chugai Seiyaku Kabushiki Kaisha	Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
TW202402792A (zh)	2017-11-28	2024-01-16	日商中外製藥股份有限公司	可調整配體結合活性的配體結合分子
AR114112A1 (es)	2018-02-15	2020-07-22	Seattle Genetics Inc	Anticuerpos de glipicano 3 y conjugados de los mismos
US20210253672A1 (en)	2018-05-30	2021-08-19	Chugai Seiyaku Kabushiki Kaisha	Ligand-binding molecule containing single domain antibody
AU2019288733C1 (en)	2018-06-22	2023-08-03	Kite Pharma, Inc.	Chimeric transmembrane proteins and uses thereof
AU2019354395A1 (en)	2018-10-01	2021-05-06	Adicet Therapeutics, Inc.	Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors
WO2020086758A1 (en)	2018-10-23	2020-04-30	Dragonfly Therapeutics, Inc.	Heterodimeric fc-fused proteins
US20220153875A1 (en)	2019-03-19	2022-05-19	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
AU2020288499A1 (en)	2019-06-05	2022-01-27	Chugai Seiyaku Kabushiki Kaisha	Antibody cleavage site-binding molecule
JPWO2020246567A1 (da)	2019-06-05	2020-12-10
EP3986922A2 (en)	2019-06-21	2022-04-27	Kite Pharma, Inc.	Tgf-beta receptors and methods of use
WO2021216916A1 (en)	2020-04-22	2021-10-28	Dragonfly Therapeutics, Inc.	Formulation, dosage regimen, and manufacturing process for heterodimeric fc-fused proteins
MX2023001120A (es)	2020-07-31	2023-02-22	Chugai Pharmaceutical Co Ltd	Composicion farmaceutica que comprende una celula que expresa un receptor quimerico.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04228089A (ja)	1990-05-15	1992-08-18	Kanegafuchi Chem Ind Co Ltd	高カルシウム血症治療・予防剤
US6214973B1 (en) *	1993-11-19	2001-04-10	Chugai Seiyaku Kabushiki Kaisha	Reshaped human antibody to human medulloblastoma cells
EP1978033A3 (en)	1995-04-27	2008-12-24	Amgen Fremont Inc.	Human antibodies derived from immunized xenomice
JP3587664B2 (ja)	1996-10-04	2004-11-10	中外製薬株式会社	再構成ヒト抗ｈｍ１．２４抗体
UA76934C2 (en) *	1996-10-04	2006-10-16	Chugai Pharmaceutical Co Ltd	Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
JP4228089B2 (ja)	1997-03-11	2009-02-25	株式会社ニコン	過電流検知機構およびそれを用いた電子閃光装置
US7361336B1 (en) *	1997-09-18	2008-04-22	Ivan Bergstein	Methods of cancer therapy targeted against a cancer stem line
US7052873B2 (en) *	1997-10-03	2006-05-30	Chugai Seiyaku Kabushiki Kaisha	Natural human antibody
JP3445153B2 (ja) *	1998-06-04	2003-09-08	富士通株式会社	電話番号一時的使用装置及び方法
TWI290832B (en) *	1999-08-23	2007-12-11	Chugai Pharmaceutical Co Ltd	Expression enhancer for HM1.24 antigen
DE60228721D1 (en) *	2001-06-22	2008-10-16	Chugai Pharmaceutical Co Ltd	Zellproliferationsinhibitoren mit anti-glypican-3-antikörper

2002
- 2002-06-21 DE DE60228721T patent/DE60228721D1/de not_active Expired - Lifetime
- 2002-06-21 WO PCT/JP2002/006237 patent/WO2003000883A1/ja active Application Filing
- 2002-06-21 PT PT02741243T patent/PT1411118E/pt unknown
- 2002-06-21 DE DE60237929T patent/DE60237929D1/de not_active Expired - Lifetime
- 2002-06-21 AT AT02741243T patent/ATE407204T1/de active
- 2002-06-21 US US10/481,524 patent/US20040236080A1/en not_active Abandoned
- 2002-06-21 KR KR1020037016776A patent/KR100877176B1/ko active IP Right Grant
- 2002-06-21 CA CA2451493A patent/CA2451493C/en not_active Expired - Lifetime
- 2002-06-21 DK DK10003378.6T patent/DK2208784T3/da active
- 2002-06-21 EP EP10003378A patent/EP2208784B1/en not_active Expired - Lifetime
- 2002-06-21 ES ES02741243T patent/ES2312586T3/es not_active Expired - Lifetime
- 2002-06-21 CN CN2007100960379A patent/CN101240022B/zh not_active Expired - Lifetime
- 2002-06-21 DK DK02741243T patent/DK1411118T3/da active
- 2002-06-21 ES ES07002896T patent/ES2353335T3/es not_active Expired - Lifetime
- 2002-06-21 ES ES10003378T patent/ES2399028T3/es not_active Expired - Lifetime
- 2002-06-21 EP EP07002896A patent/EP1780273B1/en not_active Expired - Lifetime
- 2002-06-21 AT AT07002896T patent/ATE483801T1/de not_active IP Right Cessation
- 2002-06-21 JP JP2003507268A patent/JP4281869B2/ja not_active Expired - Lifetime
- 2002-06-21 KR KR1020097019979A patent/KR100953520B1/ko active IP Right Grant
- 2002-06-21 KR KR1020087019090A patent/KR20080077295A/ko not_active Application Discontinuation
- 2002-06-21 EP EP02741243A patent/EP1411118B1/en not_active Expired - Lifetime
- 2002-06-21 PT PT100033786T patent/PT2208784E/pt unknown
- 2002-06-21 CN CNB028125703A patent/CN1314803C/zh not_active Expired - Lifetime
- 2002-06-21 AU AU2002315857A patent/AU2002315857B2/en not_active Expired
2005
- 2005-04-28 JP JP2005133154A patent/JP2005225892A/ja not_active Withdrawn
- 2005-12-15 HK HK05111542A patent/HK1079547A1/xx not_active IP Right Cessation
2006
- 2006-11-06 JP JP2006300276A patent/JP2007051159A/ja not_active Withdrawn
2007
- 2007-02-05 US US11/702,780 patent/US7744880B2/en not_active Expired - Lifetime
- 2007-03-22 AU AU2007201255A patent/AU2007201255B2/en not_active Expired
- 2007-06-25 JP JP2007165739A patent/JP2007238632A/ja active Pending
2008
- 2008-02-08 JP JP2008028527A patent/JP2008120828A/ja active Pending
- 2008-09-05 JP JP2008228128A patent/JP4347402B2/ja not_active Expired - Lifetime
- 2008-11-07 HK HK08112277.1A patent/HK1120522A1/xx not_active IP Right Cessation
2009
- 2009-04-24 JP JP2009105835A patent/JP5596935B2/ja not_active Expired - Lifetime
2010
- 2010-04-26 US US12/799,491 patent/US8263077B2/en not_active Expired - Fee Related
2013
- 2013-03-29 CY CY20131100264T patent/CY1113854T1/el unknown

Also Published As

Publication number	Publication date
PT1411118E (pt)	2008-12-09
JP2005225892A (ja)	2005-08-25
US8263077B2 (en)	2012-09-11
US20040236080A1 (en)	2004-11-25
ATE407204T1 (de)	2008-09-15
JP2009024020A (ja)	2009-02-05
ES2399028T3 (es)	2013-03-25
HK1079547A1 (en)	2006-04-07
KR20080077295A (ko)	2008-08-21
CY1113854T1 (el)	2016-07-27
EP1411118A1 (en)	2004-04-21
AU2002315857B2 (en)	2007-07-26
CN101240022A (zh)	2008-08-13
KR100953520B1 (ko)	2010-04-21
CN1314803C (zh)	2007-05-09
KR20040030699A (ko)	2004-04-09
WO2003000883A1 (en)	2003-01-03
DK1411118T3 (da)	2008-11-17
EP1780273A1 (en)	2007-05-02
JP2009161565A (ja)	2009-07-23
HK1120522A1 (en)	2009-04-03
KR20090107091A (ko)	2009-10-12
CA2451493C (en)	2016-08-23
JP4281869B2 (ja)	2009-06-17
KR100877176B1 (ko)	2009-01-07
JP2007238632A (ja)	2007-09-20
EP1780273B1 (en)	2010-10-06
CN1688692A (zh)	2005-10-26
US20110002922A1 (en)	2011-01-06
JP5596935B2 (ja)	2014-09-24
CA2451493A1 (en)	2003-01-03
JP2007051159A (ja)	2007-03-01
AU2007201255A1 (en)	2007-04-19
ES2312586T3 (es)	2009-03-01
US20070172488A1 (en)	2007-07-26
JP2008120828A (ja)	2008-05-29
ATE483801T1 (de)	2010-10-15
EP1411118A4 (en)	2005-01-26
EP2208784A1 (en)	2010-07-21
PT2208784E (pt)	2013-04-03
ES2353335T3 (es)	2011-03-01
DE60237929D1 (de)	2010-11-18
DE60228721D1 (en)	2008-10-16
JP4347402B2 (ja)	2009-10-21
EP2208784B1 (en)	2013-01-02
EP1411118B1 (en)	2008-09-03
US7744880B2 (en)	2010-06-29
CN101240022B (zh)	2012-07-18
JPWO2003000883A1 (ja)	2004-10-07
AU2007201255B2 (en)	2010-03-11

Publication	Publication Date	Title
DK2208784T3 (da)	2013-03-18	Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof
BRPI0317696B8 (pt)	2021-05-25	composição para branqueamento
ATE363280T1 (de)	2007-06-15	Verwendung von pioglitazone zur verbesserung der ketose und der azidose
GB0209891D0 (en)	2002-06-05	Novel compounds
CY1106766T1 (el)	2012-05-23	Παραγωγα πυριδινης ως αναστολεις raf κινασης
SE0102327D0 (sv)	2001-06-28	A novel engineered superantigen for human therapy
HK1060729A1 (en)	2004-08-20	Inhibitors of cruzipain and other cysteine proteases
BR0014758A (pt)	2002-07-02	Sistemas e métodos para expressão de proteìna com alto rendimento
DE50310323D1 (de)	2008-09-25	Wässrige polyurethanzubereitungen
DE50009838D1 (de)	2005-04-28	Humanes antibiotisches protein
DE60125232D1 (de)	2007-01-25	Kleines säurelösliches sporenprotein und seine verwendungen
ATE269313T1 (de)	2004-07-15	Tryptase-inhibitoren
DK1368022T3 (da)	2007-10-01	Anvendelse af en flaske indeholdende en oxaliplatinoplösning
WO2002057246A3 (en)	2002-11-21	Inhibitors of cruzipain and other cysteine proteases
ATE392644T1 (de)	2008-05-15	Alpha-(1' -hydroxyalkyl)acrylate enthaltende beschichtungsmassen
PT1244614E (pt)	2004-10-29	Inibidores de triptase
ES2421520T3 (es)	2013-09-03	Potenciador de la producción de adiponectina
DE502004012439D1 (de)	2011-06-09	Medikament und verwendung zur tumortherapie
DK1438411T3 (da)	2006-11-20	Anvendelse af aminogylcosid-resistensgen
ES2188597T3 (es)	2003-07-01	Uso de una secuencia genica promotora para el tratamiento de enfermedades reumaticas.
ATE474567T1 (de)	2010-08-15	Kombinationspräparate enthaltend 2- methylthiazolidin-2,4-dicarbonsäure
DE69825307D1 (de)	2004-09-02	Verwendung von protein h als zytostattischer wirkstoff
ATE382363T1 (de)	2008-01-15	Pharmazeutische zusammensetzung enthaltend bulbophyllum
SG145571A1 (en)	2008-09-29	Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same
ECSP992875A (es)	1999-06-01	Inhibidores de la proteina /tirosina/ cinasa /de imidazopiracina sustituidas con heterociclo